US Pharma Mergers and Acquisitions in 3Q17
Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.
Before Vivant Digital, IBM made several acquisitions in 2016 to boost its iX business. IBM acquired Ecx.io, Aperto, Resource/Ammirati, Bluewolf Group, and Expert Personal Shopper.
On October 4, 2017, IBM announced the acquisition of Vivant Digital, an Australia-based (EWA) digital and innovation agency.
Analysts Ana Gupte of Leerink Partners said in a recent client note that Amazon might enter the drug distribution market within the next two years.
Kellogg (K), like most of its packaged food manufacturing peers, is grappling with weak consumer demand for its products.
Kellogg (K) announced the acquisition of Chicago Bar Company, the manufacturer of RXBAR, for $600 million.
On October 6, 2017, Intuitive Surgical will start trading on a split-adjusted basis. It has scheduled a stock split for its shares in a ratio of 3:1.
On September 22, 2017, Abbott Laboratories (ABT) announced the FDA approval of the MR-conditional labeling for its Ellipse ICD.
DXCM stock fell following ABT’s announcement, while ABT’s stock price rose. The Vanguard Dividend Appreciation ETF (VIG) rose that day as well.
On September 27, Abbott Laboratories (ABT) announced the FDA approval of its Flash CGM (continuous glucose monitoring) device, Freestyle Libre.
The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories’ (ABT) acquisition of Alere (ALR).
Thermo Fisher Scientific continues to invest significantly in research and development as well as developing commercial capabilities, making the company one of the major medical technology players in the United States.
Permabit specializes in cleaning up corporate data to make data access faster and data storage more efficient.
On September 25, Boston Scientific (BSX) announced the launch of the Resonate family of ICD and CRT-D systems. The devices are approved by the FDA for conditional use in the MRI environment.
On September 19, 2017, Boston Scientific announced new data from its MultiSENSE (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) study.
The PAS2 study, which is a post-approval clinical trial, was conducted at 27 sites across the United States and Canada.
Conagra Brands (CAG) will report its fiscal 1Q18 sales and earnings results on Thursday, September 28.
Conagra Brands is focusing on reinventing its portfolio by shedding underperforming non-core brands and adding fast-growing popular brands through acquisitions.
Varian Medical Systems (VAR) is the leading radiation oncology technology and solutions company.
Halcyon is the company’s new treatment platform for cancer patients that visually enhances and simplifies image-guided radiotherapy treatments (or IMRT).